27 August 2019
IDT Australia Limited (ASX: IDT) is pleased to announce that the Department of Health – Office of
Drug Control has granted the Company its first Medicinal Cannabis Manufacturing Permit under the
Narcotic Drugs Act 1967.
The Permit allows IDT to manufacture and store cannabis extract at the IDT premises licensed by the
Office of Drug Control in quantities specified by the Permit.
“IDT has a long history of Manufacturing both Active Pharmaceutical Ingredients (API’s) and Finished
Dosage Forms.” said Jim Sosic IDT’s Vice President of Operations Supply and Infrastructure “This
permit complimentsIDT’s Good Manufacturing Practice (GMP) licenses, our Schedule 8 and 9 Poisons
Licensure, along with our Medicinal Cannabis Manufacturing Licence; and paves the way for IDT to
ramp‐up our activities in GMP medicinal cannabis manufacturing.”
For further information please contact:
IDT Australia Limited
Dr David Sparling – Chief Executive Officer
0417 721 972
IDT (ASX:IDT) is a public Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. It has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients.
IDT’s facilities are fully cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of
specialists within world‐class facilities, IDT provides a full‐scale service for new drug development and scale‐up, commercial active drug
manufacture as well as a variety of oral and injectable finished drug dose forms.
Read the full media release here.